Hikma Pharmaceuticals (LON: HIK)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Group in a report released on Friday. They currently have a $13.52 (900 GBX) target price on the stock.
Hikma Pharmaceuticals traded up 8.14% on Friday, hitting GBX 936.50. Hikma Pharmaceuticals has a 1-year low of GBX 580.36 and a 1-year high of GBX 785.00. The stock’s 50-day moving average is currently GBX 728.8. The company’s market cap is £1.835 billion.
A number of other firms have also recently commented on HIK. Analysts at Panmure Gordon raised their price target on shares of Hikma Pharmaceuticals from $14.10 to $15.16 in a research note to investors on Friday. They now have a “buy” rating on the stock.
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.